US EditionPublished • loading... • Updated
Caremark seeking a possible $200 copay for Novo Nordisk's Wegovy
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Caremark seeking a possible $200 copay for Novo Nordisk's Wegovy
WOONSOCKET, R.I. — Caremark, the pharmacy benefit manager owned by CVS Health, is reportedly trying to get Novo Nordisk to agree to cover a month's supply of its blockbuster GLP-1 weight loss treatment Wegovy (semaglutide) for $200 for insurance plan members.Although $200 is a steep monthly co-pay for a covered brand-name medication, it’s still significantly lower than the $500 price Novo Nordisk charges through its direct-to-consumer platform f…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
